C
156.98
0.30 (0.19%)
| Previous Close | 156.68 |
| Open | 156.58 |
| Volume | 649,016 |
| Avg. Volume (3M) | 890,756 |
| Market Cap | 7,725,644,800 |
| Price / Earnings (Forward) | 16.45 |
| Price / Sales | 1.98 |
| Price / Book | 2.30 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -0.49% |
| Operating Margin (TTM) | 13.62% |
| Diluted EPS (TTM) | -0.600 |
| Quarterly Revenue Growth (YOY) | -2.70% |
| Quarterly Earnings Growth (YOY) | -62.20% |
| Total Debt/Equity (MRQ) | 92.21% |
| Current Ratio (MRQ) | 1.43 |
| Operating Cash Flow (TTM) | 776.39 M |
| Levered Free Cash Flow (TTM) | 625.62 M |
| Return on Assets (TTM) | 4.26% |
| Return on Equity (TTM) | -0.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Charles River Laboratories Inte | Bullish | Bearish |
AIStockmoo Score
-0.2
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Average | -0.20 |
|
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 1.01% |
| % Held by Institutions | 111.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vanguard Group Inc | 30 Jun 2025 | 5,811,754 |
| Wellington Management Group Llp | 30 Jun 2025 | 3,767,805 |
| Blackrock, Inc. | 30 Jun 2025 | 3,656,132 |
| Allspring Global Investments Holdings, Llc | 30 Jun 2025 | 2,291,126 |
| State Street Corp | 30 Jun 2025 | 1,858,787 |
| Nomura Holdings Inc | 30 Jun 2025 | 1,569,269 |
| Ariel Investments, Llc | 30 Jun 2025 | 1,415,348 |
| Invesco Ltd. | 30 Jun 2025 | 1,237,143 |
| Geode Capital Management, Llc | 30 Jun 2025 | 1,232,230 |
| Harris Associates L P | 30 Jun 2025 | 1,162,935 |
| Bank Of America Corp /De/ | 30 Jun 2025 | 1,026,013 |
| Dimensional Fund Advisors Lp | 30 Jun 2025 | 1,010,698 |
| Mackenzie Financial Corp | 30 Jun 2025 | 1,002,049 |
| Earnest Partners Llc | 30 Jun 2025 | 998,257 |
| Morgan Stanley | 30 Jun 2025 | 754,863 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 200.00 (Citigroup, 27.41%) | Buy |
| Median | 182.00 (15.94%) | |
| Low | 160.00 (JP Morgan, 1.92%) | Hold |
| Average | 179.40 (14.28%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 148.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 08 Aug 2025 | 190.00 (21.03%) | Buy | 148.74 |
| 09 Jul 2025 | 180.00 (14.66%) | Buy | 158.97 | |
| Barclays | 07 Aug 2025 | 165.00 (5.11%) | Hold | 149.78 |
| JP Morgan | 07 Aug 2025 | 160.00 (1.92%) | Hold | 149.78 |
| Citigroup | 09 Jul 2025 | 200.00 (27.40%) | Buy | 158.97 |
| Redburn Atlantic | 23 May 2025 | 182.00 (15.94%) | Buy | 136.73 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LAPLUME JOSEPH W | - | 149.78 | -400 | -59,912 |
| Aggregate Net Quantity | -400 | |||
| Aggregate Net Value ($) | -59,912 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 149.78 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LAPLUME JOSEPH W | Officer | 07 Aug 2025 | Sell (-) | 400 | 149.78 | 59,912 |
| Date | Type | Details |
|---|---|---|
| 06 Aug 2025 | Announcement | Charles River Laboratories Announces Second-Quarter 2025 Results |
| 31 Jul 2025 | Announcement | Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership |
| 22 Jul 2025 | Announcement | Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development |
| 15 Jul 2025 | Announcement | Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call |
| 16 Jun 2025 | Announcement | Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment |
| 02 Jun 2025 | Announcement | Charles River Laboratories to Present at William Blair and Jefferies Conferences |
| 28 May 2025 | Announcement | Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research |
| 5Y Average Dividend Yield | 0.00% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 28 Nov 1996 | 20 Nov 1996 | 12 Dec 1996 | 0.1 Cash |
| 29 Oct 1996 | 23 Oct 1996 | 12 Dec 1996 | 0.1 Cash |
| 26 Sep 1996 | 19 Sep 1996 | 14 Nov 1996 | 0.1 Cash |
| 28 Aug 1996 | 21 Aug 1996 | 14 Nov 1996 | 0.1 Cash |
| 29 Jul 1996 | 23 Jul 1996 | 14 Nov 1996 | 0.1 Cash |
| 26 Jun 1996 | 20 Jun 1996 | 14 Aug 1996 | 0.1 Cash |
| 29 May 1996 | 20 May 1996 | 14 Aug 1996 | 0.1 Cash |
| 26 Apr 1996 | 18 Apr 1996 | 14 Aug 1996 | 0.1 Cash |
| 27 Mar 1996 | 22 Mar 1996 | 15 May 1996 | 0.1 Cash |
| 27 Dec 1995 | 20 Dec 1995 | 14 Feb 1996 | 0.1 Cash |
| 28 Nov 1995 | 20 Nov 1995 | 14 Feb 1996 | 0.1 Cash |
| 27 Oct 1995 | 17 Oct 1995 | 14 Feb 1996 | 0.1 Cash |
| 27 Sep 1995 | 19 Sep 1995 | 14 Nov 1995 | 0.1 Cash |
| 29 Aug 1995 | 18 Aug 1995 | 14 Nov 1995 | 0.1 Cash |
| 27 Jul 1995 | 18 Jul 1995 | 14 Nov 1995 | 0.1 Cash |
| 28 Jun 1995 | 19 Jun 1995 | 14 Aug 1995 | 0.1 Cash |
| 24 May 1995 | 17 May 1995 | 14 Aug 1995 | 0.1 Cash |
| 24 Apr 1995 | 20 Apr 1995 | 14 Aug 1995 | 0.1 Cash |
| Show more | |||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |